ANGN (Angion Biomedica) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Angion Biomedica LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Angion Biomedica's long-term debt to total assests ratio for the quarter that ended in Mar. 2023 was 0.00.

Angion Biomedica's long-term debt to total assets ratio declined from Mar. 2022 (0.04) to Mar. 2023 (0.00). It may suggest that Angion Biomedica is progressively becoming less dependent on debt to grow their business.

Angion Biomedica LT-Debt-to-Total-Asset Historical Data

The historical data trend for Angion Biomedica's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Angion Biomedica LT-Debt-to-Total-Asset Chart

Angion Biomedica Annual Data

Trend

Dec12

Dec13

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.33

0.10

0.04

0.05

Angion Biomedica Quarterly Data
	Jun13	Dec13	Mar14	Jun14	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.05	0.05	0.05	-

Angion Biomedica LT-Debt-to-Total-Asset Calculation

Angion Biomedica's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	2.649	/	52.79
	=	0.05

Angion Biomedica's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (Q: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2023 )	/	Total Assets (Q: Mar. 2023 )
	=	0.07	/	41.767
	=

Angion Biomedica (NAS:ANGN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Angion Biomedica LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Angion Biomedica's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Angion Biomedica Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Angion Biomedica Corp (NAS:ANGN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-57 Wells Avenue, Suite 14, Newton, MA, USA, 02459

Website

https://www.angion.com

Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Executives

Jay Venkatesan	director, officer: See Remarks	C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Allen Nissenson	director	601 HAWAII ST., EL SEGUNDO CA 90245
John F. Neylan	officer: See Remarks	750 LEXINGTON AVENUE, NEW YORK NY 10022
Gregory S Curhan	officer: See Remarks	600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Jennifer J Rhodes	officer: See Remarks	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Itzhak Goldberg	officer: See Remarks	51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
Victor F Ganzi	director
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Eisa-abc Llc	10 percent owner	C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553